Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 196-203

  Vacas, Eva ^a   Arenas, M Isabel ^a   Muñoz Moreno, Laura ^a   Bajo, Ana M ^a   Sánchez Chapado, Manuel ^a,b   Prieto, Juan C ^a   Carmena, María J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

CcRCC; MMP; NF B; VEGF; VIP

Indexed keywords

BETA ACTIN; BETA CATENIN; CD34 ANTIGEN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P21; PROTEIN P53; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA ACTIN GENE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; P21 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BETA CATENIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; VASOACTIVE INTESTINAL PEPTIDE;

MUS; MUS MUSCULUS;

EID: 84879004452     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.033     Document Type: Article

References (42)

1. Noble H., Page K. Renal cell cancer: nurses' role in prevention and management. Br. J. Nurs. 2012, 21:S18-S22.
2. Motzer R.J., Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007, 370:2071-2073.
3. Nickerson M.L., Jaeger E., Shi Y., Durocher J.A., Mahurkar S., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., Navratilova M., Szeszenia-Dabrowska N., Mates D., Mukeria A., Holcatova I., Schmidt L.S., Toro J.R., Karami S., Hung R., Gerard G.F., Linehan W.M., Merino M., Zbar B., Boffetta P., Brennan P., Rothman N., Chow W.H., Waldman F.M., Moore L.E. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 2008, 14:4726-4734.
4. Li L., Gao Y., Zhang L., Zeng J., He D., Sun Y. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating surviving and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett. 2008, 272:61-69.
5. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20:161-168.
6. Ak P., Levine A.J. P53 and NF-κB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 2010, 24:3643-3652.
7. Kawata N., Nagane Y., Hirakata H., Ichinose T., Okada Y., Yamaguchi K., Takahashi S. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 2007, 69:1049-1053.
8. Morais C., Gobe G., Johnson D.W., Healy H. The emerging role of nuclear factor kappa B in renal cell carcinoma. Int. J. Biochem. Cell Biol. 2011, 43:1537-1549.
9. Peruzzi B., Athauda G., Bottaro D.P. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl. Acad. Sci. USA 2006, 103:14531-14536.
10. Laburthe M., Couvineau A., Tan V. Class II G-protein coupled receptors for VIP and PACAP: structure, model of activation and pharmacology. Peptides 2007, 28:1631-1639.
11. Abad C., Gomariz R.P., Waschek J.A. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr. Top. Med. Chem. 2006, 6:151-163.
12. Gomariz R.P., Juarranz Y., Abad C., Arranz A., Leceta J., Martínez C. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. NY Acad. Sci. 2006, 1070:51-74.
13. Smalley S.G., Barrow P.A., Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin. Exp. Immunol. 2009, 157:225-234.
14. Vacas E., Bajo A.M., Schally A.V., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma. Mol. Cell. Endocrinol. 2013, 365:212-222.
15. Vacas E., Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Schally A.V., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochim. Biophys. Acta 1823, 2012:1676-1685.
16. Fernández-Martínez A.B., Bajo A.M., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate 2009, 69:774-786.
17. Fernández-Martínez A.B., Bajo A.M., Arenas M.I., Sánchez-Chapado M., Prieto J.C., Carmena M.J. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1. Cancer Lett. 2010, 299:11-21.
18. Fernández-Martínez A.B., Carmena M.J., Arenas M.I., Bajo A.M., Prieto J.C., Sánchez-Chapado M. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Histol. Histopathol. 2012, 27:1093-1101.
19. Valdehita A., Bajo A.M., Schally A.V., Varga J.L., Carmena M.J., Prieto J.C. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol. Cell. Endocrinol. 2009, 302:41-48.
20. Valdehita A., Bajo A.M., Fernández-Martínez A.B., Arenas M.I., Vacas E., Valenzuela P., Ruíz-Villaespesa A., Prieto J.C., Carmena M.J. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides 2010, 31:2035-2045.
21. Valdehita A., Carmena M.J., Bajo A.M., Prieto J.C. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol. Cell. Endocrinol. 2012, 348:241-246.
22. Li M., Maderdrut J.L., Lertora J.J., Arimura A., Batuman V. Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases. Regul. Pept. 2008, 145:24-32.
23. Small D.M., Coombes J.S., Bennet N., Johnson D.W., Gobe G.C. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 2012, 17:311-321.
24. González-Rey E., Varela N., Chorny A., Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des. 2007, 13:1113-1139.
25. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
26. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10:1343-1374.
27. Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i104-i108.
28. Dey A., Verma C.S., Lane D.P. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br. J. Cancer 2008, 98:4-8.
29. Kluger H.M., Siddiqui S.F., Angeletti C., Sznol M., Kelly W.K., Molinaro A.M., Camp R.L. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab. Invest. 2008, 88:962-972.
30. Banumathy G., Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther. 2010, 10:658-664.
31. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
32. Stickle N.H., Cheng L.S., Watson I.R., Alon N., Malkin D., Irwin M.S., Ohh M. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat. Res. 2005, 578:23-32.
33. Vaid M., Prasad R., Sun Q., Katiyar K. Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells. PloS One 2011, 6:e23000.
34. Evans A.J., Russell R.C., Roche O., Burry T.N., Fish J.E., Chow V.W.K., Yim W.Y., Saravanan A., Maynard M.A., Gervais M.L., Sufan R.I., Roberts A.M., Wilson L.A., Betten M., Vandewalle C., Berx G., Marsden P.A., Irwin M.S., Teh B.T., Jewett M.A.S., Ohh M. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1, and Snail. Mol. Cell. Biol. 2007, 27:157-169.
35. Linehan W.M., Rubin J.S., Bottaro D.P. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int. J. Biochem. Cell Biol. 2009, 41:753-756.
36. Russell R.C., Ohh M. The role of VHL in the regulation of E-cadherin: a newconnectionin an old pathway. Cell Cycle 2007, 6:56-59.
37. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 2007, 17:45-51.
38. Yilmaz M., Christofori G. Mechanisms of motility in metastasizing cells. Mol. Cancer Res. 2010, 8:629-642.
39. Kugler A., Hemmerlein B., Thelen P., Kallerhoff M., Radzun H.J., Ringert R.H. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J. Urol. 1998, 160:1914-1918.
40. Abdel-Wahed M.M., Asaad N.Y., Aleskandarany M. Expression of matrix metalloproteinase-2 in renal cell carcinoma. J. Egypt Natl. Canc. Inst. 2004, 16:168-177.
41. Sumi T., Nakatani T., Yoshida H., Hyun Y., Yasui T., Matsumoto Y., Nakagawa E., Sugimura K., Kawashima H., Ishiko O. Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma. Oncol. Rep. 2003, 10:567-570.
42. Cho N.H., Shim H.S., Rha S.Y., Kang S.H., Hong S.H., Choi Y.D., Hong S.J., Cho S.H. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur. Urol. 2003, 44:560-565.